Best of ASCO - 2014 Annual Meeting

 

Welcome

Immune Checkpoint Inhibitors

Developmental Immunotherapy and Tumor Immunobiology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A clinical prognosis model for Asian advanced melanoma patients receiving immunotherapy.

Xuan Wang

e14081

A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer.

Cristiane Jeyce Gomes-Lima

e14096

A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.

Timothy A Yap

TPS2652

A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.

Jeffrey Yachnin

TPS2653

A machine learning based prediction model of anti-PD-1 therapy response using noninvasive clinical information and blood markers of lung cancer patients.

Beung-Chul AHN

e14138

A novel noninvasive biomarker based on peripheral PD-1posi CD8 T-cell receptor repertoire correlated with clinical outcomes to immunotherapy in non-small cell lung cancer.

Jie-Fei Han

e14174

A phase I study evaluating COM701 in patients with advanced solid tumors.

Drew W. Rasco

TPS2657

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

Laura Quan Man Chow

2514

A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.

Jason J. Luke

TPS2661

A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.

Matthew David Hellmann

TPS2654

A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer.

Raanan Alter

TPS2663

A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.

Oliver Klein

2570

A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and/or pulmonary involvement.

Sara I. Pai

2502

A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).

Joleen Marie Hubbard

e14145

A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Rui-hua Xu

TPS2655

A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).

Jian-Ming Xu

TPS2656

A retrospective cohort study of anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.

Danyang Sun

e14100

A retrospective review of nutritional status and immunotherapy in lung cancer.

Chung-Shien Lee

e14112

A RNA signature predicts outcomes in immune checkpoint blockade treated gastrointestinal cancer patients.

Zhihao Lu

e14071

An immune response-associated genomic model to predict early resistance to PD1/PD-L1 blockade among real-world TMB-high Chinese cancer patients.

Qiang Xu

e14167

Analysis of early mortality in randomized clinical trials evaluating anti-PD-1/PD-L1 antibodies: A systematic analysis by the United States Food and Drug Administration (FDA).

Flora Mulkey

2516

Anti-PD-1 therapy combined with chemotherapy in patients with advanced pancreas cancer in a real-world clinical setting.

Danyang Sun

e14103

Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.

Ruth Perets

2558

Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM).

Miguel Angel Villalona-Calero

2555

Association between MDM2/MDM4 amplification and PD-1/PD-L1 inhibitors-related hyperprogressive disease: A pan-cancer analysis.

Weiqiang Ju

2557

Association between past medical history (PMH) of autoimmune events and adverse events of special interest (AESI).

Jamie Renee Brewer

2565

Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer.

Qiyun Ou

e14087

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Toni K. Choueiri

101

Blocking LILRB and KIR receptors by B57 open conformers induces potent antitumor activity and acts synergistically with checkpoint blockade inhibition.

Christoph Renner

e14137

Bone metastases treated with immune checkpoint inhibitors: A single center experience.

Punita Grover

e14105

Burden of copy number alterations predicts outcomes in immune checkpoint blockade treated gastrointestinal cancer patients.

Zhihao Lu

e14068

Cardiovascular complications of immune checkpoint inhibitor therapy.

Samip R. Master

2568

Characteristics and treatment of rheumatologic adverse events associated with immune checkpoint inhibitors: A multicentric prospective cohort study.

Amine Mouamnia

e14133

Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ.

Wendy S. Rubinstein

2566

Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities.

Bilal A. Siddiqui

e14118

Combined treatment of patients with bone metastases from various cancers with nivolumab plus denosumab: A retrospective study.

Yukinori Ozaki

e14153

Comparison of panendoscopy directed biopsies with percutaneous and image-guided biopsies during immune checkpoint inhibitor therapy.

Ahmad F Hashmi

e14084

DC-HIL/Gpnmb checkpoint blockade as a synergistic combination for stereotactic ablative radiation (SAbR).

Vijay Ramani

e14129

Defining real-world criteria for immune-related adverse events (irAEs).

PRABHSIMRANJOT SINGH

e14172

Development of imjSCORE for early prediction of response to nivolumab among patients with advanced cancer.

Milos Josef Janicek

e14169

Differences in prescribing and patient demographics of cki agents among United States patients < 65 and 65+ years old.

William H Angel

e14097

Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB).

Natalie Vokes

2515

DNA repair pathway alterations and correlation with immunotherapy response.

Tatiana Hernandez-Guerrero

e14150

Dual blockade of PD-1 and PD-L1 is effective but causes severe pneumonitis in lung metastasis: Syngeneic mice study for validation of clinical observation.

Yu-Jen Chen

e14115

Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs).

Chris Morehouse

2563

Effect of antibiotic exposure in patients with metastatic melanoma treated with PD-1 inhibitor or CTLA-4 inhibitor or a combination of both.

Vidit Kapoor

e14141

Effect of exonic microsatellite instability of B2M on the predictability of MSI/dMMR for immunotherapy.

Jia Wei

2576

Effect of smoking on the efficacy of immune checkpoint inhibitors in advanced cancers: A systematic review and meta-analysis.

Chia Ching Lee

e14109

Efficacy and a novel clinicopathologic-genomic nomogram of atezolizumab in advanced non-small cell lung cancer (POPLAR and OAK): A combined analysis of two multicenter, randomized, phase II/III trials.

Yunfang Yu

2573

Efficacy and safety of nivolumab monotherapy as the late line for patients with advanced gastric cancer in the real-world.

Tetsuya Kusumoto

e14074

Efficacy and safety of PD-1 inhibitors in combination with chemotherapy versus chemotherapy as first and second line treatment in advanced gastric and gastroesophageal junction cancer: Preliminary data from a real-world setting.

Yi Hu

e14079

Endocrinopathies associated with immune checkpoint inhibitors: Standard of care at veterans administration medical centers.

Brett Johnson

e14148

Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).

Rika Kizawa

e14110

Evaluating the role of the COX2/PGE2 pathway in anti-melanoma immunity.

Michelle Ferreira

e14114

Evaluation of radiotherapeutic and immune-modulatory response to whole brain radiotherapy or stereotactic radiosurgery in patients with brain metastases from malignant melanoma treated with or without ipilimumab (ELEKTRA).

Jessica Cecile Hassel

e14104

Expecting the unexpected.

Blessie Elizabeth Nelson

e14066

Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.

Niels Halama

e14143

Expression of PD-L1 and IDO in hormone receptor negative DCIS.

Sneha Deepak Phadke

e14116

Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.

Alessio Cortellini

2559

Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis.

Gol Minoo Golshani

2561

Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).

Charlotte L. Zuur

2575

First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.

Kyriakos P. Papadopoulos

2508

Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of clinical trials.

Faisal Ali

e14117

Gene expression profiles of peripheral blood mononuclear cells from patients with advanced non-small cell lung cancer treated with anti-PD-1 monoclonal antibodies.

Jie Wu

e14107

Genetic determinants of adverse events in cancer patients receiving immune checkpoint inhibitors.

Noha Abdel-Wahab

2586

GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin’s lymphoma: Preliminary result of a phase II clinical trial.

Yuqin Song

e14072

High prevalence of IBD-associated genetic variants in patients (pts) with immune checkpoint inhibitor (ICI) enteritis/colitis.

Shilpa Grover

2582

Host metabolic factors and prognosis in patients treated with immune checkpoint inhibitors for advanced malignancies.

Federica Biello

e14162

Immune checkpoint inhibitor toxicity in the clinical practice setting.

Laura Schmidt

e14128

Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.

Hamzah Abu-Sbeih

2577

Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.

Giulia Grizzi

e14130

Immune-related toxicities in non-small cell lung cancer: Real-life predictors of outcome to checkpoint inhibitors?

Emanuela Romano

e14135

Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.

Roberto Pili

2572

Immunotherapy discontinuation and outcome: A multicenter real-life experience.

Maria Bassanelli

e14075

Immunotherapy efficacy and patients' age: A systematic review and meta-analysis.

Jianchun Duan

e14168

Immunotherapy efficacy and safety of programmed cell death 1 (PD-1) versus programmed death ligand-1 (PD-L1) inhibitors in pan-cancer: A systematic review and meta-analysis.

Jianchun Duan

e14113

Immunotherapy with checkpoint inhibitors in mismatch repair deficient (dMMR) cancers: Looking for a needle in a haystack— But, joy on finding one.

Amit Rauthan

e14073

Immunotherapy: Auto-immune toxicity as a predictive factor of response.

Marine Valery

e14086

Impact of IDO1 expression and inhibition on the sensitivity of anti-PD-1.

Jian Zhu

e14094

Impact of pericardial effusion for patients receiving immune checkpoint inhibitors.

Abir Khan

e14121

Incidence and characteristics of emergency department presentations during immune checkpoint inhibitor therapy.

Daniel Arnold Smith

e14164

Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).

Bicky Thapa

e14151

Intra and perinodular CT delta radiomic features associated with early response to predict overall survival (OS) in immunotherapy-treated non-small cell lung cancer (NSCLC): A multisite multi-agent study.

Prateek Prasanna

2588

IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer.

Nashat Y. Gabrail

2560

Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.

Alexander M. M. Eggermont

2512

IRX-2 therapy with PD-L1 blockade in immunocompetent animal model.

Lu Wen

e14149

Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population.

Ulka N. Vaishampayan

e14136

Is inmunotherapy a safe treatment in bladder cancer? A retrospective study in daily practice.

Natalia Vidal Casinello

e14083

JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.

David Michael Hyman

TPS2660

Major lab abnormalities as biomarkers in patients treated with immune checkpoint inhibitors: A single institution study of 1044 patients.

Kai Laukamp

e14108

Measuring the long-term “tail of curve” survival benefits in oncology trials: A comparison of the ASCO Value Framework and the ESMO Magnitude of Clinical Benefit Scale.

Louis Everest

2585

MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).

Philippe Alexandre Cassier

2579

Multidisciplinary approach to immune related adverse events as a potential biomarker: Single institution experience in non-small cell lung cancer.

Sooyoung Martin

e14124

Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.

Joshua Dean Horton

2574

Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

Manish R. Patel

2562

Organ dysfunction (dys) and clinical outcomes in patients (pts) treated with immune checkpoint inhibitors (ICIs).

QI LIU

2569

Outcomes after early initiation of nonsteroidal immunosuppressive therapy in patients with immune checkpoint inhibitor-induced colitis.

Yinghong Wang

2571

Outcomes and toxicities in sarcopenic patients with metastatic solid tumors treated with check point inhibitors.

Laura Haik

e14166

Overcoming genetically based resistance mechanisms to PD-1 blockade.

Davis Yuri Torrejon

2584

Patient survival with immune checkpoint inhibitors and targeted agents in phase 1 trials: A propensity score weighted analysis.

Itziar Gardeazabal

2580

Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.

Salvatore Siena

TPS2659

Pembrolizumab versus the standard of care for cancer therapy: A meta-analysis of 12 KEYNOTE trials comparing overall survival.

Nathaniel Parker

e14159

Phase I study of pembrolizumab in people with HIV and cancer.

Thomas S. Uldrick

2500

Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Funda Meric-Bernstam

2507

Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): Preliminary analysis of the colorectal cancer (CRC) cohort.

Osama E. Rahma

e14160

Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.

María González-Cao

2501

Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.

Nataliya Volodymyrivna Uboha

2553

Preclinical characterization and efficacy of 4R9, a novel immune checkpoint blockade targeting CEACAM1 for cancer therapy.

Jae-Chul Lee

e14155

Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies.

Jeremy Waight

e14126

Predictive value of baseline clinicopathological factors in non-small cell lung cancer (NSCLC) patients on checkpoint inhibitors (CPI).

James Newman

e14119

Predictors and outcomes of thyroid dysfunction with immunotherapy: A single institution observational experience.

Ankit Mangla

e14134

Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC).

Siyang Wang

2556

Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.

Jermaine Coward

2554

Prevalence of immunotherapy-related adverse events due to checkpoint inhibitors: First report in Mexico.

Elina Alexandra Rodriguez Melendez

e14090

Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.

Alexander M. M. Eggermont

2517

Prognostic score for second or further line immunotherapy in advanced non-small cell lung cancer (aNSCLC): An external validation.

Arsela Prelaj

e14077

Prognostic value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with advanced solid tumors treated with PD-1 inhibitors.

Miguel Gonzalez Velez

e14132

Prospective cardiac function monitoring in immunotherapy-treated patients.

Mandar A Aras

e14157

Proton pump inhibitors and response to immune check-point inhibitors: Single center study.

Asaad Trabolsi

e14092

Rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in melanoma and lung cancer patients with autoimmune diseases.

David Andrew Bender

e14140

Real-life use of nivolumab and pembrolizumab in four adult university teaching hospitals in Québec, Canada.

Nathalie Letarte

e14125

Real-world Merkel cell carcinoma outcomes from a tertiary care center.

Theresa N Canavan

e14098

Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.

Neil J. Shah

2587

Real-world outcomes with immuno-oncology (IO) therapies: A prospective, observational cohort study in patients (pts) with advanced melanoma (OPTIMIzE).

John M. Kirkwood

e14144

Real-world use and survival outcomes of immune checkpoint inhibitors in patients with non-small cell lung cancer.

Bora Youn

e14111

Recurrence-free survival (RFS) and objective response rate (ORR) phase 1/2 study of intralesional (IL) neoadjuvant (neo) anti-PD1 agents (aPD1) for stage IIIB-IV melanoma (MEL).

Igor Samoylenko

e14171

Recurrent and de-novo autoimmune hemolytic anemia in patients treated with immunotherapy for advanced cancer.

Natasha A. Jain

e14170

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

Shota Fukuoka

2522

Response rate to chemotherapy after disease progression with anti-PD-1/PD-L1 in metastatic cancer.

Munaf Al-Kadhimi

e14088

Results of an Italian CORE-IMMUNO study: Safety and clinical-related biomarkers as predictors of immunotherapy (IT) benefit in real-world treatment of various advanced tumors (ATs).

Cristina Masini

e14156

Review of therapeutic approaches for B-cell malignancies with immune checkpoint blockade and chimeric antigen receptor t-cell therapies: Development, benefits, and limitations.

Priya Hays

e14069

Safety and tolerability of immune checkpoint therapies and related adverse effects at a tertiary care hospital in Saudi Arabia.

Mohammed Al Nuhait

e14082

Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles.

Kyung Hwan Kim

2564

SLAMF8, a novel biomarker for personalized immune checkpoint blockade therapy in gastrointestinal cancer.

Qun Zhang

e14078

Surrogate end points for overall survival in patients with advanced non-small-cell lung cancer in trials of immunotherapy.

Qiyun Ou

e14122

SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.

Sandip Pravin Patel

TPS2658

T cell receptor β-chain repertoire analysis to reveal potential predictive biomarker for the use of immune checkpoint blockade in patients with advanced solid tumors.

Ye Li

e14152

The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity.

Rohit K. Jain

TPS2662

The safety and tolerability of PD-1/PDL-1 inhibitors in hematologic malignancies: A meta-analysis.

Phyo Thazin Myint

e14131

Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience.

Manuel Sureda

e14089

Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients.

Jie Wang

e14067

Toxicities of single agent and combination immune checkpoint inhibitors in patients with autoimmune diseases.

Samuel Cytryn

e14176

Toxicity of PD-1/CTLA-4 inhibitor immunotherapy among elderly patients.

Vidit Kapoor

e14139

Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.

Arsen Osipov

2578

Understanding contribution and independence of multiple biomarkers for predicting response to atezolizumab.

Parantu K. Shah

2567

Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients.

Paul Johannet

2581